Rituximab for refractory polymyositis: An open-label prospective study

Journal of Rheumatology

Volumn 34, Issue 9, 2007, Pages 1864-1868

  Mok, Chi Chiu ^a   Ho, Ling Yin ^a   To, Chi Hung ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

B cell depletion; Inflammatory myopathies; Resistant; Rituximab

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; RITUXIMAB; TACROLIMUS;

ADULT; ALLERGIC REACTION; ARTICLE; CASE REPORT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE RESISTANCE; DRUG EFFICACY; DRUG MEGADOSE; ELECTROMYOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; INFECTION; INJECTION SITE REACTION; LYMPHOCYTE COUNT; MALE; MUSCLE BIOPSY; MUSCLE STRENGTH; POLYMYOSITIS; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DISABLED PERSONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH; PILOT PROJECTS; POLYMYOSITIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 35948960659     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Torres C, Belmonte R, Carmona L, et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 2006;39:205-15.
2. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
3. Baer AN. Advances in the therapy of idiopathic inflammatory myopathies. Curr Opin Rheumatol 2006;18:236-41.
4. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
5. Looney RJ. B cell-targeted therapy in diseases other than rheumatoid arthritis. J Rheumatol 2005;32 Suppl 73:25-8.
6. Levine TD. Rituximab in the treatment of dermatomyositis. An open-label pilot study. Arthritis Rheum 2005;52:601-7.
7. Noss EH, Hausner-Sypek, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006;33:1021-6.
8. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005;32:1369-70.
9. Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005;11:264-6.
10. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7.
11. Rider LG, Giannini EH, Harris-Love M, et al. International Myositis Assessment and Clinical Studies Group. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003;30:603-17.
12. Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45:627-9.
13. US Food and Drug Administration (FDA) MedWatch Safety Information 2006. Available at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#Rituxan. Accessed June 15, 2007.